10-Q 1 pcrx-20230930.htm 10-Q - PCRX - 9.30.2023 pcrx-20230930
000139681412/312023Q3FALSEhttp://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006MemberP0D0.909.013932433100013968142023-01-012023-09-3000013968142023-11-01xbrli:shares00013968142023-09-30iso4217:USD00013968142022-12-31iso4217:USDxbrli:shares0001396814us-gaap:ProductMember2023-07-012023-09-300001396814us-gaap:ProductMember2022-07-012022-09-300001396814us-gaap:ProductMember2023-01-012023-09-300001396814us-gaap:ProductMember2022-01-012022-09-300001396814us-gaap:RoyaltyMember2023-07-012023-09-300001396814us-gaap:RoyaltyMember2022-07-012022-09-300001396814us-gaap:RoyaltyMember2023-01-012023-09-300001396814us-gaap:RoyaltyMember2022-01-012022-09-3000013968142023-07-012023-09-3000013968142022-07-012022-09-3000013968142022-01-012022-09-300001396814us-gaap:CommonStockMember2023-06-300001396814us-gaap:AdditionalPaidInCapitalMember2023-06-300001396814us-gaap:RetainedEarningsMember2023-06-300001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000013968142023-06-300001396814us-gaap:CommonStockMember2023-07-012023-09-300001396814us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001396814us-gaap:RetainedEarningsMember2023-07-012023-09-300001396814us-gaap:CommonStockMember2023-09-300001396814us-gaap:AdditionalPaidInCapitalMember2023-09-300001396814us-gaap:RetainedEarningsMember2023-09-300001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001396814us-gaap:CommonStockMember2022-06-300001396814us-gaap:AdditionalPaidInCapitalMember2022-06-300001396814us-gaap:RetainedEarningsMember2022-06-300001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000013968142022-06-300001396814us-gaap:CommonStockMember2022-07-012022-09-300001396814us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001396814us-gaap:RetainedEarningsMember2022-07-012022-09-300001396814us-gaap:CommonStockMember2022-09-300001396814us-gaap:AdditionalPaidInCapitalMember2022-09-300001396814us-gaap:RetainedEarningsMember2022-09-300001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-3000013968142022-09-300001396814us-gaap:CommonStockMember2022-12-310001396814us-gaap:AdditionalPaidInCapitalMember2022-12-310001396814us-gaap:RetainedEarningsMember2022-12-310001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001396814us-gaap:CommonStockMember2023-01-012023-09-300001396814us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001396814us-gaap:RetainedEarningsMember2023-01-012023-09-300001396814us-gaap:CommonStockMember2021-12-310001396814us-gaap:AdditionalPaidInCapitalMember2021-12-310001396814us-gaap:RetainedEarningsMember2021-12-310001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100013968142021-12-3100013968142021-01-012021-12-310001396814us-gaap:AdditionalPaidInCapitalMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001396814srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2021-12-310001396814srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001396814us-gaap:CommonStockMember2022-01-012022-09-300001396814us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300001396814us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300001396814us-gaap:RetainedEarningsMember2022-01-012022-09-300001396814pcrx:ConvertibleSeniorNotesDue2022Member2023-01-012023-09-300001396814pcrx:ConvertibleSeniorNotesDue2022Member2022-01-012022-09-300001396814pcrx:ConvertibleSeniorNotesDue2024Member2023-01-012023-09-300001396814pcrx:ConvertibleSeniorNotesDue2024Member2022-01-012022-09-300001396814pcrx:TermLoanBFacilityMember2023-01-012023-09-300001396814pcrx:TermLoanBFacilityMember2022-01-012022-09-300001396814pcrx:TermLoanAFacilityMember2023-01-012023-09-300001396814pcrx:TermLoanAFacilityMember2022-01-012022-09-300001396814us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-30pcrx:productpcrx:segment0001396814us-gaap:CustomerConcentrationRiskMember2023-01-012023-09-30pcrx:customer0001396814us-gaap:SalesRevenueNetMemberpcrx:LargestCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-30xbrli:pure0001396814us-gaap:SalesRevenueNetMemberpcrx:LargestCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001396814us-gaap:SalesRevenueNetMemberpcrx:LargestCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300001396814us-gaap:SalesRevenueNetMemberpcrx:LargestCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001396814pcrx:SecondLargestCustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001396814pcrx:SecondLargestCustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001396814pcrx:SecondLargestCustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300001396814pcrx:SecondLargestCustomerMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001396814us-gaap:SalesRevenueNetMemberpcrx:ThirdLargestCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001396814us-gaap:SalesRevenueNetMemberpcrx:ThirdLargestCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001396814us-gaap:SalesRevenueNetMemberpcrx:ThirdLargestCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300001396814us-gaap:SalesRevenueNetMemberpcrx:ThirdLargestCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001396814pcrx:ThreeLargestCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001396814pcrx:ThreeLargestCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001396814pcrx:ThreeLargestCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300001396814pcrx:ThreeLargestCustomersMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001396814srt:MinimumMember2023-01-012023-09-300001396814srt:MaximumMember2023-01-012023-09-300001396814pcrx:EXPARELbupivacaineliposomeinjectablesuspensionMember2023-07-012023-09-300001396814pcrx:EXPARELbupivacaineliposomeinjectablesuspensionMember2022-07-012022-09-300001396814pcrx:EXPARELbupivacaineliposomeinjectablesuspensionMember2023-01-012023-09-300001396814pcrx:EXPARELbupivacaineliposomeinjectablesuspensionMember2022-01-012022-09-300001396814pcrx:ZILRETTAMember2023-07-012023-09-300001396814pcrx:ZILRETTAMember2022-07-012022-09-300001396814pcrx:ZILRETTAMember2023-01-012023-09-300001396814pcrx:ZILRETTAMember2022-01-012022-09-300001396814pcrx:IoveraMember2023-07-012023-09-300001396814pcrx:IoveraMember2022-07-012022-09-300001396814pcrx:IoveraMember2023-01-012023-09-300001396814pcrx:IoveraMember2022-01-012022-09-300001396814pcrx:BupivacaineLiposomeInjectableSuspensionMember2023-07-012023-09-300001396814pcrx:BupivacaineLiposomeInjectableSuspensionMember2022-07-012022-09-300001396814pcrx:BupivacaineLiposomeInjectableSuspensionMember2023-01-012023-09-300001396814pcrx:BupivacaineLiposomeInjectableSuspensionMember2022-01-012022-09-300001396814us-gaap:MachineryAndEquipmentMember2023-09-300001396814us-gaap:MachineryAndEquipmentMember2022-12-310001396814us-gaap:LeaseholdImprovementsMember2023-09-300001396814us-gaap:LeaseholdImprovementsMember2022-12-310001396814pcrx:ComputerEquipmentAndSoftwareMember2023-09-300001396814pcrx:ComputerEquipmentAndSoftwareMember2022-12-310001396814us-gaap:FurnitureAndFixturesMember2023-09-300001396814us-gaap:FurnitureAndFixturesMember2022-12-310001396814us-gaap:ConstructionInProgressMember2023-09-300001396814us-gaap:ConstructionInProgressMember2022-12-310001396814us-gaap:ConstructionInProgressMember2023-07-012023-09-300001396814us-gaap:ConstructionInProgressMember2022-07-012022-09-300001396814us-gaap:ConstructionInProgressMember2023-01-012023-09-300001396814us-gaap:ConstructionInProgressMember2022-01-012022-09-300001396814us-gaap:LeaseholdImprovementsMembersrt:EuropeMember2023-09-300001396814us-gaap:LeaseholdImprovementsMembersrt:EuropeMember2022-12-31pcrx:lease0001396814stpr:MA2023-07-012023-09-300001396814stpr:MA2023-09-300001396814pcrx:UponAnnualNetSalesReachingDollar500.0MillionThresholdMemberpcrx:SkyePharmaHoldingIncMember2022-03-310001396814us-gaap:DevelopedTechnologyRightsMember2023-09-300001396814us-gaap:DevelopedTechnologyRightsMember2023-01-012023-09-300001396814us-gaap:CustomerRelationshipsMember2023-09-300001396814us-gaap:CustomerRelationshipsMember2023-01-012023-09-300001396814us-gaap:InProcessResearchAndDevelopmentMember2023-09-300001396814us-gaap:DevelopedTechnologyRightsMember2022-12-310001396814us-gaap:DevelopedTechnologyRightsMember2023-01-012023-03-310001396814us-gaap:CustomerRelationshipsMember2022-12-310001396814us-gaap:CustomerRelationshipsMember2023-01-012023-03-310001396814us-gaap:InProcessResearchAndDevelopmentMember2022-12-310001396814us-gaap:SecuredDebtMemberpcrx:TermLoanAFacilityDueMarch2028Member2023-09-300001396814us-gaap:SecuredDebtMemberpcrx:TermLoanAFacilityDueMarch2028Member2022-12-310001396814us-gaap:SecuredDebtMemberpcrx:TermLoanBFacilityDue2026Member2023-09-300001396814us-gaap:SecuredDebtMemberpcrx:TermLoanBFacilityDue2026Member2022-12-310001396814pcrx:ConvertibleSeniorNotesDue2025Member2023-09-300001396814pcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:UnsecuredDebtMember2023-09-300001396814pcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:UnsecuredDebtMember2022-12-310001396814pcrx:ConvertibleSeniorNotesDueMay2024Member2023-09-300001396814us-gaap:UnsecuredDebtMemberpcrx:ConvertibleSeniorNotesDueMay2024Member2023-09-300001396814us-gaap:UnsecuredDebtMemberpcrx:ConvertibleSeniorNotesDueMay2024Member2022-12-310001396814pcrx:SecuredAndUnsecuredDebtMember2023-09-300001396814pcrx:SecuredAndUnsecuredDebtMember2022-12-310001396814us-gaap:SecuredDebtMemberpcrx:TermLoanAFacilityDueMarch2028Member2023-03-310001396814us-gaap:SecuredDebtMemberpcrx:TermLoanAFacilityDueMarch2028Member2023-03-312023-03-310001396814us-gaap:SecuredDebtMemberpcrx:TermLoanAFacilityDueMarch2028Member2023-06-302023-06-300001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMembersrt:ScenarioForecastMember2025-03-312025-03-310001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMembersrt:ScenarioForecastMember2028-03-310001396814us-gaap:SecuredDebtMemberpcrx:TermLoanAFacilityDueMarch2028Member2023-07-012023-09-300001396814pcrx:TermLoanAFacilityDueMarch2028Member2023-09-300001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:BaseRateMembersrt:MinimumMember2023-09-300001396814srt:MaximumMemberpcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:BaseRateMember2023-09-300001396814pcrx:SecuredOvernightFinancingRateSOFRMemberpcrx:TermLoanAFacilityDueMarch2028Membersrt:MinimumMember2023-09-300001396814srt:MaximumMemberpcrx:SecuredOvernightFinancingRateSOFRMemberpcrx:TermLoanAFacilityDueMarch2028Member2023-09-300001396814us-gaap:SecuredDebtMemberpcrx:TermLoanAFacilityDueMarch2028Member2023-01-012023-09-300001396814us-gaap:SecuredDebtMemberpcrx:TermLoanBFacilityDue2026Member2021-12-310001396814us-gaap:SecuredDebtMemberpcrx:TermLoanBFacilityDue2026Member2021-12-012021-12-310001396814us-gaap:SecuredDebtMemberpcrx:TermLoanBFacilityDue2026Member2023-03-312023-03-310001396814us-gaap:SecuredDebtMemberpcrx:TermLoanBFacilityDue2026Member2023-03-310001396814us-gaap:SecuredDebtMemberpcrx:TermLoanBFacilityDue2026Member2023-01-012023-09-300001396814pcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:UnsecuredDebtMember2020-07-310001396814pcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:UnsecuredDebtMember2020-07-012020-07-310001396814pcrx:ConvertibleSeniorNotesDue2022Memberus-gaap:UnsecuredDebtMember2020-07-310001396814pcrx:ConvertibleSeniorNotesDue2022Memberus-gaap:UnsecuredDebtMember2020-07-012020-07-310001396814pcrx:DebtRedemptionTermsPriorToFebruary32023Memberpcrx:ConvertibleSeniorNotesDue2025Member2023-07-012023-09-30pcrx:trading_day0001396814pcrx:ConvertibleSeniorNotesDue2025Member2020-07-310001396814pcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:UnsecuredDebtMember2023-01-012023-09-300001396814pcrx:ConvertibleSeniorNotesDue2025Memberpcrx:DebtRedemptionTermsOnOrAfterAugust12023Member2023-01-012023-09-300001396814pcrx:ConvertibleSeniorNotesDue2024Memberus-gaap:UnsecuredDebtMemberpcrx:FlexionTherapeuticsIncMember2017-05-020001396814pcrx:ConvertibleSeniorNotesDue2024Member2021-12-062022-01-060001396814pcrx:ConvertibleSeniorNotesDue2024Memberus-gaap:UnsecuredDebtMember2022-01-070001396814pcrx:ConvertibleSeniorNotesDue2022Memberus-gaap:UnsecuredDebtMember2017-03-012017-03-310001396814pcrx:ConvertibleSeniorNotesDue2022Memberus-gaap:UnsecuredDebtMember2017-03-310001396814pcrx:ConvertibleSeniorNotesDue2022Memberus-gaap:UnsecuredDebtMember2022-04-012022-04-010001396814us-gaap:CommonStockMember2022-04-012022-04-010001396814pcrx:ConvertibleSeniorNotesDue2025Member2023-01-012023-09-300001396814us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300001396814us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2023-09-300001396814us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001396814us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SecuredDebtMember2023-09-300001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001396814us-gaap:FairValueInputsLevel2Memberpcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001396814pcrx:TermLoanAFacilityDueMarch2028Memberus-gaap:SecuredDebtMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001396814us-gaap:CarryingReportedAmountFairValueDisclosureMemberpcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:UnsecuredDebtMember2023-09-300001396814pcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:UnsecuredDebtMember2023-09-300001396814us-gaap:FairValueInputsLevel2Memberpcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:UnsecuredDebtMember2023-09-300001396814us-gaap:FairValueInputsLevel3Memberpcrx:ConvertibleSeniorNotesDue2025Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:UnsecuredDebtMember2023-09-300001396814pcrx:ConvertibleSeniorNotesDue2024Memberus-gaap:UnsecuredDebtMember2023-09-300001396814us-gaap:CarryingReportedAmountFairValueDisclosureMemberpcrx:ConvertibleSeniorNotesDue2024Memberus-gaap:UnsecuredDebtMember2023-09-300001396814pcrx:ConvertibleSeniorNotesDue2024Memberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:UnsecuredDebtMember2023-09-300001396814us-gaap:FairValueInputsLevel2Memberpcrx:ConvertibleSeniorNotesDue2024Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:UnsecuredDebtMember2023-09-300001396814pcrx:ConvertibleSeniorNotesDue2024Memberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:UnsecuredDebtMember2023-09-300001396814srt:MaximumMemberpcrx:ConvertibleSeniorNotesDue2025Member2023-01-012023-09-300001396814us-gaap:EquitySecuritiesMember2021-12-310001396814pcrx:ConvertibleNotesReceivableMember2021-12-310001396814us-gaap:EquitySecuritiesMember2022-01-012022-12-310001396814pcrx:ConvertibleNotesReceivableMember2022-01-012022-12-3100013968142022-01-012022-12-310001396814us-gaap:EquitySecuritiesMember2022-12-310001396814pcrx:ConvertibleNotesReceivableMember2022-12-310001396814us-gaap:EquitySecuritiesMember2023-01-012023-09-300001396814pcrx:ConvertibleNotesReceivableMember2023-01-012023-09-300001396814us-gaap:EquitySecuritiesMember2023-09-300001396814pcrx:ConvertibleNotesReceivableMember2023-09-300001396814pcrx:FlexionAndMyoScienceAcquisitionMember2023-09-300001396814pcrx:FlexionAndMyoScienceAcquisitionMember2022-12-310001396814pcrx:FlexionAcquisitionMember2021-11-300001396814pcrx:FlexionAcquisitionMember2023-09-300001396814pcrx:FlexionAcquisitionMember2023-01-012023-09-300001396814pcrx:FlexionAcquisitionMember2023-07-012023-09-300001396814pcrx:FlexionAcquisitionMember2022-07-012022-09-300001396814pcrx:FlexionAcquisitionMember2022-01-012022-09-300001396814pcrx:FlexionAcquisitionMembersrt:WeightedAverageMemberpcrx:ContingentConsiderationMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Member2023-09-300001396814pcrx:FlexionAcquisitionMembersrt:WeightedAverageMemberpcrx:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Memberpcrx:MeasurementInputProbabilityOfSuccessOfRegulatoryMilestonesMember2023-09-300001396814pcrx:FlexionAcquisitionMember2022-12-310001396814pcrx:MyoscienceAcquisitionMember2019-04-012019-04-300001396814pcrx:MyoscienceAcquisitionMember2023-09-300001396814pcrx:MeasurementInputExpectedMilestonePaymentMemberpcrx:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Memberpcrx:MyoscienceAcquisitionMember2023-09-300001396814pcrx:MyoscienceAcquisitionMember2022-12-310001396814pcrx:MyoscienceAcquisitionMember2022-07-012022-09-300001396814pcrx:MyoscienceAcquisitionMember2022-01-012022-09-300001396814pcrx:FlexionAcquisitionMemberpcrx:ContingentConsiderationMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Membersrt:MinimumMember2023-09-300001396814srt:MaximumMemberpcrx:FlexionAcquisitionMemberpcrx:ContingentConsiderationMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Member2023-09-300001396814pcrx:FlexionAcquisitionMemberpcrx:ContingentConsiderationMemberpcrx:MeasurementInputExpectedMilestonePaymentMemberus-gaap:FairValueInputsLevel3Membersrt:MinimumMember2023-09-300001396814srt:MaximumMemberpcrx:FlexionAcquisitionMemberpcrx:ContingentConsiderationMemberpcrx:MeasurementInputExpectedMilestonePaymentMemberus-gaap:FairValueInputsLevel3Member2023-09-300001396814pcrx:ContingentConsiderationMember2021-12-310001396814pcrx:ContingentConsiderationMember2022-01-012022-12-310001396814pcrx:ContingentConsiderationMember2022-12-310001396814pcrx:ContingentConsiderationMember2023-01-012023-09-300001396814pcrx:ContingentConsiderationMember2023-09-300001396814us-gaap:ShortTermInvestmentsMemberus-gaap:AssetBackedSecuritiesMember2023-09-300001396814us-gaap:ShortTermInvestmentsMemberus-gaap:CommercialPaperMember2023-09-300001396814us-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300001396814us-gaap:ShortTermInvestmentsMemberus-gaap:USTreasuryBondSecuritiesMember2023-09-300001396814us-gaap:ShortTermInvestmentsMemberus-gaap:AssetBackedSecuritiesMember2022-12-310001396814us-gaap:ShortTermInvestmentsMemberus-gaap:CommercialPaperMember2022-12-310001396814us-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001396814us-gaap:ShortTermInvestmentsMemberus-gaap:USTreasuryBondSecuritiesMember2022-12-310001396814us-gaap:ShortTermInvestmentsMember2022-12-310001396814pcrx:LongTermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001396814pcrx:LongTermInvestmentsMemberus-gaap:USTreasuryBondSecuritiesMember2022-12-310001396814pcrx:LongTermInvestmentsMember2022-12-31pcrx:wholesaler0001396814us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberpcrx:MajorCustomerOneMember2023-01-012023-09-300001396814pcrx:MajorCustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-09-300001396814pcrx:MajorCustomerThreeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-09-300001396814us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberpcrx:MajorCustomerOneMember2022-01-012022-12-310001396814pcrx:MajorCustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2022-01-012022-12-310001396814pcrx:MajorCustomerThreeMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2022-01-012022-12-310001396814us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310001396814us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001396814us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-09-300001396814us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-09-300001396814us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-09-300001396814us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300001396814us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310001396814us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001396814us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-09-300001396814us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-09-300001396814us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-09-300001396814us-gaap:AccumulatedTranslationAdjustmentMember2022-09-3000013968142023-06-012023-06-300001396814us-gaap:CostOfSalesMember2023-07-012023-09-300001396814us-gaap:CostOfSalesMember2022-07-012022-09-300001396814us-gaap:CostOfSalesMember2023-01-012023-09-300001396814us-gaap:CostOfSalesMember2022-01-012022-09-300001396814us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001396814us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001396814us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001396814us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001396814us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001396814us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300001396814us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001396814us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300001396814us-gaap:RestrictedStockUnitsRSUMember2022-12-310001396814us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001396814us-gaap:RestrictedStockUnitsRSUMember2023-09-300001396814us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001396814us-gaap:EmployeeStockMember2023-01-012023-09-30pcrx:offeringPeriod0001396814us-gaap:AccountingStandardsUpdate202006Member2023-07-012023-09-300001396814us-gaap:AccountingStandardsUpdate202006Member2022-07-012022-09-300001396814us-gaap:AccountingStandardsUpdate202006Member2023-01-012023-09-300001396814us-gaap:AccountingStandardsUpdate202006Member2022-01-012022-09-300001396814us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001396814us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001396814us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001396814us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001396814us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001396814us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001396814us-gaap:EmployeeStockMember2023-07-012023-09-300001396814us-gaap:EmployeeStockMember2022-07-012022-09-300001396814us-gaap:EmployeeStockMember2022-01-012022-09-300001396814us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001396814us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001396814us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001396814us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001396814us-gaap:SeniorNotesMember2023-07-012023-09-300001396814us-gaap:SeniorNotesMember2022-07-012022-09-300001396814us-gaap:SeniorNotesMember2023-01-012023-09-300001396814us-gaap:SeniorNotesMember2022-01-012022-09-300001396814us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001396814us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001396814us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001396814us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001396814us-gaap:EmployeeStockMember2023-07-012023-09-300001396814us-gaap:EmployeeStockMember2022-07-012022-09-300001396814us-gaap:EmployeeStockMember2023-01-012023-09-300001396814us-gaap:EmployeeStockMember2022-01-012022-09-300001396814us-gaap:TradingRevenueMemberus-gaap:SeniorNotesMember2022-07-012022-09-300001396814us-gaap:TradingRevenueMemberus-gaap:SeniorNotesMember2023-01-012023-09-300001396814pcrx:AcquisitionRelatedFeesMember2023-07-012023-09-300001396814pcrx:AcquisitionRelatedFeesMember2022-07-012022-09-300001396814pcrx:AcquisitionRelatedFeesMember2023-01-012023-09-300001396814pcrx:AcquisitionRelatedFeesMember2022-01-012022-09-300001396814us-gaap:OtherRestructuringMember2023-07-012023-09-300001396814us-gaap:OtherRestructuringMember2022-07-012022-09-300001396814us-gaap:OtherRestructuringMember2023-01-012023-09-300001396814us-gaap:OtherRestructuringMember2022-01-012022-09-300001396814pcrx:FlexionTherapeuticsIncMember2023-07-012023-09-300001396814pcrx:FlexionTherapeuticsIncMember2022-07-012022-09-300001396814pcrx:FlexionTherapeuticsIncMember2023-01-012023-09-300001396814pcrx:FlexionTherapeuticsIncMember2022-01-012022-09-300001396814pcrx:MyoscienceAcquisitionMember2023-07-012023-09-300001396814pcrx:MyoscienceAcquisitionMember2023-01-012023-09-300001396814pcrx:LegalFeesMemberpcrx:FlexionAcquisitionMember2023-07-012023-09-300001396814pcrx:LegalFeesMemberpcrx:FlexionAcquisitionMember2023-01-012023-09-300001396814pcrx:LegalFeesMemberpcrx:FlexionAcquisitionMember2022-07-012022-09-300001396814pcrx:LegalFeesMemberpcrx:FlexionAcquisitionMember2022-01-012022-09-300001396814us-gaap:OneTimeTerminationBenefitsMember2023-07-012023-09-300001396814us-gaap:OneTimeTerminationBenefitsMember2023-01-012023-09-300001396814pcrx:FortisMember2020-10-012020-10-3100013968142023-08-080001396814pcrx:AchievementOfDevelopmentAndRegulatoryMilestonesMemberpcrx:GeneQuineMemberpcrx:FlexionTherapeuticsIncMember2017-02-280001396814pcrx:AchievementOfDevelopmentAndRegulatoryMilestonesMemberpcrx:GeneQuineMemberpcrx:FlexionTherapeuticsIncMember2017-02-012017-02-280001396814pcrx:CharlesAReinhartIIIMember2023-07-012023-09-300001396814pcrx:KristenWilliamsMember2023-07-012023-09-300001396814pcrx:RoyWinstonMember2023-07-012023-09-300001396814pcrx:DirectorsAndExecutiveOfficersPlanTerminationMember2023-07-012023-09-30


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2023
 
OR

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from     to
Commission File Number: 001-35060

pacirabiosciencesa05.jpg

PACIRA BIOSCIENCES, INC.
(Exact Name of Registrant as Specified in its Charter)
 
Delaware51-0619477
(State or Other Jurisdiction of
Incorporation or Organization)		(I.R.S. Employer
 Identification No.)

5401 West Kennedy Boulevard, Suite 890
Tampa, Florida 33609
(Address and Zip Code of Principal Executive Offices)
(813) 553-6680
(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Common Stock, par value $0.001 per sharePCRXNasdaq Global Select Market


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes  ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.) ☒ Yes  ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes  ☒ No

As of November 1, 2023, 46,437,704 shares of the registrant’s common stock, $0.001 par value per share, were outstanding.

PACIRA BIOSCIENCES, INC.
QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2023

TABLE OF CONTENTS
  Page #
 
 
 
 
 
 
   
 

Pacira BioSciences, Inc. | Q3 2023 Form 10-Q | Page 3
PART I — FINANCIAL INFORMATION
Item 1. FINANCIAL STATEMENTS (Unaudited)
PACIRA BIOSCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(Unaudited)
September 30,
2023		December 31,
2022
ASSETS
Current assets:  
     Cash and cash equivalents$99,119 $104,139 
     Short-term available-for-sale investments136,069 184,512 
     Accounts receivable, net96,956 98,397 
     Inventories, net96,520 96,063 
     Prepaid expenses and other current assets18,591 15,223 
          Total current assets447,255 498,334 
Noncurrent available-for-sale investments— 37,209 
Fixed assets, net175,783 183,512 
Right-of-use assets, net63,394 70,877 
Goodwill163,243 163,243 
Intangible assets, net497,580 540,546 
Deferred tax assets151,660 160,309 
Investments and other assets35,547 27,170 
          Total assets$1,534,462 $1,681,200 
LIABILITIES AND STOCKHOLDERS’ EQUITY  
Current liabilities:  
     Accounts payable$16,511 $15,220 
     Accrued expenses59,884 89,785 
     Lease liabilities8,625 9,121 
     Current portion of convertible senior notes, net8,641 — 
Current portion of long-term debt, net— 33,648 
          Total current liabilities93,661 147,774 
Convertible senior notes, net397,976 404,767 
Long-term debt, net117,965 251,056 
Lease liabilities57,089 64,802 
Contingent consideration24,275 28,122 
Other liabilities11,945 9,669 
          Total liabilities702,911 906,190 
Commitments and contingencies (Note 15)
Stockholders’ equity:  
Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at September 30, 2023 and December 31, 2022
— — 
Common stock, par value $0.001; 250,000,000 shares authorized; 46,426,836 and 45,927,790 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively
46 46 
     Additional paid-in capital963,181 924,095 
     Accumulated deficit(131,666)(148,751)
     Accumulated other comprehensive loss(10)(380)
          Total stockholders’ equity831,551 775,010 
          Total liabilities and stockholders’ equity$1,534,462 $1,681,200 
See accompanying notes to condensed consolidated financial statements.
Pacira BioSciences, Inc. | Q3 2023 Form 10-Q | Page 4
PACIRA BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended
September 30,		Nine Months Ended
September 30,
 2023202220232022
Revenues:    
Net product sales$163,583 $166,560 $492,481 $492,563 
Royalty revenue343 906 1,253 2,305 
          Total revenues163,926 167,466 493,734 494,868 
Operating expenses:    
Cost of goods sold39,750 50,678 136,977 137,379 
Research and development20,830 19,405 56,794 67,292 
Selling, general and administrative67,947 61,283 203,640 190,546 
Amortization of acquired intangible assets14,322 14,322 42,966 42,966 
Contingent consideration charges (gains), restructuring charges and other3,356 489 (1,150)(13,232)
          Total operating expenses146,205 146,177 439,227 424,951 
Income from operations17,721 21,289 54,507 69,917 
Other (expense) income:    
Interest income2,766 1,234 8,019 1,757 
Interest expense(3,464)(9,856)(16,918)(28,935)
Loss on early extinguishment of debt— — (16,926)— 
Other, net(422)(10,598)(701)(11,369)
          Total other expense, net(1,120)(19,220)(26,526)(38,547)
Income before income taxes16,601 2,069 27,981 31,370 
Income tax expense(5,743)(2,762)(10,896)(5,359)
Net income (loss)$10,858 $(693)$17,085 $26,011 
Net income (loss) per share:    
Basic net income (loss) per common share$0.23 $(0.02)$0.37 $0.57 
Diluted net income (loss) per common share$0.23 $(0.02)$0.37 $0.56 
Weighted average common shares outstanding:  
     Basic46,416 45,831 46,151 45,400 
     Diluted52,067 45,831 46,343 52,220 
 
See accompanying notes to condensed consolidated financial statements.
Pacira BioSciences, Inc. | Q3 2023 Form 10-Q | Page 5
PACIRA BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(In thousands)
(Unaudited)
Three Months Ended
September 30,		Nine Months Ended
September 30,
 2023202220232022
Net income (loss)$10,858 $(693)$17,085 $26,011 
Other comprehensive income (loss):  
Net unrealized gain (loss) on investments, net of tax146 (163)362 (1,056)
Foreign currency translation adjustments17 98 8 219 
Total other comprehensive income (loss)163 (65)370 (837)
Comprehensive income (loss)$11,021 $(758)$17,455 $25,174 
 
See accompanying notes to condensed consolidated financial statements.
Pacira BioSciences, Inc. | Q3 2023 Form 10-Q | Page 6
PACIRA BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022
(In thousands)
(Unaudited)
 Common StockAdditional
Paid-In
Capital		Accumulated
Deficit		Accumulated Other Comprehensive Loss 
 SharesAmountTotal
Balance at June 30, 202346,409 $46 $950,626 $(142,524)$(173)$807,975 
Exercise of stock options1 — 25 — — 25 
Vested restricted stock units17 — — — — — 
Stock-based compensation— — 12,530 — — 12,530 
Other comprehensive income (Note 10)— — — — 163 163 
Net income— — — 10,858 — 10,858 
Balance at September 30, 202346,427 $46 $963,181 $(131,666)$(10)$831,551 

Common StockAdditional
Paid-In
Capital		Accumulated
Deficit		Accumulated Other Comprehensive Loss
SharesAmountTotal
Balance at June 30, 202245,802 $46 $895,151 $(137,956)$(605)$756,636 
Exercise of stock options37 — 1,563 — — 1,563 
Vested restricted stock units25 — — — — — 
Stock-based compensation— — 12,682 — — 12,682 
Other comprehensive loss (Note 10)— — — — (65)(65)
Net loss— — — (693)— (693)
Balance at September 30, 202245,864 $46 $909,396 $(138,649)$(670)$770,123 

See accompanying notes to condensed consolidated financial statements.
Pacira BioSciences, Inc. | Q3 2023 Form 10-Q | Page 7
PACIRA BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(In thousands)
(Unaudited)
 Common StockAdditional
Paid-In
Capital		Accumulated
Deficit		Accumulated Other Comprehensive Loss 
 SharesAmountTotal
Balance at December 31, 202245,928 $46 $924,095 $(148,751)$(380)$775,010 
Exercise of stock options63 — 1,939 — — 1,939 
Vested restricted stock units386 — — — — — 
Common stock issued under employee stock
purchase plan		50 — 1,672 — — 1,672 
Stock-based compensation— — 35,475 — — 35,475 
Other comprehensive income (Note 10)— — — — 370 370 
Net income— — — 17,085 — 17,085 
Balance at September 30, 202346,427 $46 $963,181 $(131,666)$(10)$831,551 
Common StockAdditional
Paid-In
Capital		Accumulated
Deficit		Accumulated Other Comprehensive (Loss) Income
SharesAmountTotal
Balance at December 31, 202144,734 $45 $942,091 $(211,895)$167 $730,408 
Reclassification of the equity component of convertible senior notes to liabilities upon adoption of Accounting Standards Update 2020-06 (1)
— — (96,468)47,235 — (49,233)
Exercise of stock options667 1 23,497 — — 23,498 
Vested restricted stock units324 — — — — — 
Common stock issued under employee stock
purchase plan		37 — 1,821 — — 1,821 
Stock-based compensation— — 35,415 — — 35,415 
Issuance of common stock upon conversion of 2022 convertible senior notes102 — 3,040 — — 3,040 
Other comprehensive loss (Note 10)— — — — (837)(837)
Net income— — — 26,011 — 26,011 
Balance at September 30, 202245,864 $46 $909,396 $(138,649)$(670)$770,123 
(1) Effective January 1, 2022, the Company adopted Accounting Standards Update 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) on a modified retrospective method of transition. As a result, the Company no longer separately presents in equity an embedded conversion feature for its convertible debt.

See accompanying notes to condensed consolidated financial statements.
Pacira BioSciences, Inc. | Q3 2023 Form 10-Q | Page 8
PACIRA BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
 (In thousands)
(Unaudited)
Nine Months Ended
September 30,
 20232022
Operating activities:  
Net income$17,085 $26,011 
Adjustments to reconcile net income to net cash provided by operating activities:  
Deferred taxes9,014 2,895 
Depreciation of fixed assets and amortization of intangible assets57,089 61,095 
Amortization of debt issuance costs2,311 2,957 
Amortization of debt discount728 2,107 
Loss on early extinguishment of debt16,926 — 
Stock-based compensation35,475 35,415 
Changes in contingent consideration(3,847)(23,394)
Impairment of investment— 10,000 
Other losses2,415 377 
Changes in operating assets and liabilities:  
Accounts receivable, net1,440 2,847 
Inventories, net(457)1,751 
Prepaid expenses and other assets(6,986)(568)
Accounts payable1,988 4,681 
Accrued expenses and income taxes payable(26,156)(23,560)
Other liabilities40 623 
Net cash provided by operating activities107,065 103,237 
Investing activities:  
Purchases of fixed assets(13,363)(24,584)
Purchases of available-for-sale investments(111,682)(319,426)
Sales of available-for-sale investments200,970 152,636 
Payment of contingent consideration— (32,000)
Purchases of equity and debt investments(6,758)(13,000)
Net cash provided by (used in) investing activities69,167 (236,374)
Financing activities:  
Proceeds from exercises of stock options1,939 23,482 
Proceeds from shares issued under employee stock purchase plan1,672 1,820 
Proceeds from Term loan A facility149,550 —
Repayment of 2022 convertible senior notes— (156,960)
Repayment of 2024 convertible senior notes— (192,609)
Repayment of Term loan B facility(296,875)(18,750)
Repayment of Term loan A facility(30,625)— 
Debt extinguishment costs(5,750)— 
Payment of debt issuance and financing costs(1,163)— 
Net cash used in financing activities(181,252)(343,017)
Net decrease in cash and cash equivalents(5,020)(476,154)
Cash and cash equivalents, beginning of period104,139 585,578 
Cash and cash equivalents, end of period$99,119 $109,424 
Supplemental cash flow information: 
Cash paid for interest$24,931 $23,620 
Cash paid for income taxes, net of refunds$2,072 $4,216 
Non-cash investing and financing activities:  
Issuance of common stock from conversion of 2022 convertible senior notes$— $3,040 
Fixed assets included in accounts payable and accrued liabilities$1,470 $5,486 
See accompanying notes to condensed consolidated financial statements.
Pacira BioSciences, Inc. | Q3 2023 Form 10-Q | Page 9
PACIRA BIOSCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
 
NOTE 1—DESCRIPTION OF BUSINESS
Pacira BioSciences, Inc. and its subsidiaries (collectively, the “Company” or “Pacira”) is the industry leader in its commitment to non-opioid pain management and providing non-opioid pain management options to as many patients as possible to redefine the role of opioids as rescue therapy only. The Company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain and spasticity. The Company’s long-acting, local analgesic, EXPAREL® (bupivacaine liposome injectable suspension), was commercially launched in the United States, or U.S., in April 2012 and approved in select European countries and the United Kingdom, or U.K., in November 2021. EXPAREL utilizes the Company’s proprietary multivesicular liposome (pMVL) drug delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In November 2021, the Company acquired Flexion Therapeutics, Inc., or Flexion (the “Flexion Acquisition”), and added ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) to its product portfolio. ZILRETTA is the first and only extended-release, intra-articular (meaning in the joint) injection indicated for the management of osteoarthritis, or OA, knee pain. In April 2019, the Company added iovera°® to its commercial offering with the acquisition of MyoScience, Inc., or MyoScience (the “MyoScience Acquisition”). The iovera° system is a handheld cryoanalgesia device used to deliver a precise, controlled application of cold temperature to targeted nerves.
Pacira is subject to risks common to companies in similar industries and stages, including, but not limited to, competition from larger companies, reliance on revenue from three products, reliance on a limited number of wholesalers, reliance on a limited number of manufacturing sites, new technological innovations, dependence on key personnel, reliance on third-party service providers and sole source suppliers, protection of proprietary technology, compliance with government regulations and risks related to cybersecurity.
The Company is managed and operated as a single business focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. The Company is managed by a single management team, and, consistent with its organizational structure, the Chief Executive Officer—who is the Company’s chief operating decision maker—manages and allocates resources at a consolidated level. Accordingly, the Company views its business as one reportable operating segment to evaluate its performance, allocate resources, set operational targets and forecast its future financial results.
NOTE 2—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation and Principles of Consolidation
These interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”), for interim reporting. Pursuant to these rules and regulations, certain information and footnote disclosures normally included in complete annual financial statements have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report”).
The condensed consolidated financial statements at September 30, 2023, and for the three and nine-month periods ended September 30, 2023 and 2022, are unaudited, but include all adjustments (consisting of only normal recurring adjustments) which, in the opinion of management, are necessary to present fairly the financial information set forth herein in accordance with GAAP. The condensed consolidated balance sheet at December 31, 2022 is derived from the audited consolidated financial statements included in the Company’s 2022 Annual Report. The condensed consolidated financial statements as presented reflect certain reclassifications from previously issued financial statements to conform to the current year presentation. The accounts of wholly-owned subsidiaries are included in the condensed consolidated financial statements. Intercompany accounts and transactions have been eliminated in consolidation.
The results of operations for these interim periods are not necessarily indicative of results that may be expected for any other interim periods or for the full year.
Pacira BioSciences, Inc. | Q3 2023 Form 10-Q | Page 10
Concentration of Major Customers
    The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers (including AmerisourceBergen Health Corporation, Cardinal Health, Inc. and McKesson Drug Company), but shipments of the product are sent directly to individual accounts, such as hospitals, ambulatory surgery centers and individual doctors. The Company also sells EXPAREL directly to ambulatory surgery centers and physicians. The Company sells ZILRETTA primarily to specialty distributors and specialty pharmacies, who then subsequently resell ZILRETTA to physicians, clinics and certain medical centers or hospitals. The Company also contracts directly with healthcare providers and intermediaries such as Group Purchasing Organizations, or GPOs. The Company sells its bupivacaine liposome injectable suspension for veterinary use to a third-party licensee in the U.S. and sells iovera° directly to end users.
The table below includes the percentage of revenues comprised by the Company’s three largest wholesalers in each period presented:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
 Largest wholesaler33%31%33%31%
 Second largest wholesaler24%22%24%23%
 Third largest wholesaler19%22%20%22%
     Total76%75%77%76%
NOTE 3—REVENUE
Revenue from Contracts with Customers
The Company’s net product sales consist of (i) EXPAREL in the U.S., the European Union, or E.U., and the U.K.; (ii) ZILRETTA in the U.S.; (iii) iovera° in the U.S., Canada and the E.U. and (iv) sales of its bupivacaine liposome injectable suspension for veterinary use. Royalty revenues are related to a collaborative licensing agreement from the sale of its bupivacaine liposome injectable suspension for veterinary use. The Company does not consider revenue from sources other than sales of EXPAREL and ZILRETTA to be material sources of its consolidated revenue. As such, the following disclosure is limited to revenue associated with net product sales of EXPAREL and ZILRETTA.
Net Product Sales
The Company sells EXPAREL through a drop-ship program under which orders are processed through wholesalers based on orders of the product placed by end-users, namely hospitals, ambulatory surgery centers and healthcare provider offices. EXPAREL is delivered directly to the end-user without the wholesaler ever taking physical possession of the product. The Company primarily sells ZILRETTA to specialty distributors and specialty pharmacies, who then subsequently resell ZILRETTA to physicians, clinics and certain medical centers or hospitals. The Company also contracts directly with healthcare providers and intermediaries such as GPOs. Product revenue is recognized when control of the promised goods are transferred to the customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods. EXPAREL and ZILRETTA revenues are recorded at the time the products are transferred to the customer.
Revenues from sales of products are recorded net of returns allowances, prompt payment discounts, service fees, government rebates, volume rebates and chargebacks. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of the sale, using the most likely amount method, except for returns, which is based on the expected value method. The Company includes these estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized for such transaction will not occur, or when the uncertainty associated with the variable consideration is resolved.
Chargebacks for fees and discounts to qualified government healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified Department of Veteran Affairs hospitals and 340B entities at prices lower than the list prices charged to other customers. The 340B Drug Discount Program is a U.S. federal government program that requires participating drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at reduced prices. Customers charge the Company for the difference between the product payment and the statutory selling price to the qualified entity. Reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and trade receivables, net. Chargeback amounts are generally determined at the time of sale to the qualified government healthcare provider by customers, and the Company generally issues credits for such
Pacira BioSciences, Inc. | Q3 2023 Form 10-Q | Page 11
amounts within weeks of the customer’s notification to the Company of the sale. Reserves for chargebacks consist of credits that the Company expects to issue for units that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit.
The calculation for some of these items requires management to make estimates based on sales data, historical return data, contracts, statutory requirements and other related information that may become known in the future. The adequacy of these provisions is reviewed on a quarterly basis.
Accounts Receivable
The majority of accounts receivable arise from product sales and represent amounts due from wholesalers, hospitals, ambulatory surgery centers, specialty distributors, specialty pharmacies and individual physicians. Payment terms generally range from zero to four months from the date of the transaction, and accordingly, there is no significant financing component.
Performance Obligations
A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Accounting Standards Codification, or ASC, 606. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.
At contract inception, the Company assesses the goods promised in its contracts with customers and identifies a performance obligation for each promise to transfer to the customer a good that is distinct. When identifying individual performance obligations, the Company considers all goods promised in the contract regardless of whether explicitly stated in the customer contract or implied by customary business practices. The Company’s contracts with customers require it to transfer an individual distinct product, which represents a single performance obligation. The Company’s performance obligation with respect to its product sales is satisfied at a point in time, which transfers control upon delivery of EXPAREL and ZILRETTA to its customers. The Company considers control to have transferred upon delivery because the customer has legal title to the asset, physical possession of the asset has been transferred, the customer has significant risks and rewards of ownership of the asset and the Company has a present right to payment at that time.
Disaggregated Revenue
The following table represents disaggregated net product sales in the periods presented as follows (in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Net product sales:
   EXPAREL$128,667 $132,642 $394,202 $398,854 
   ZILRETTA28,798 26,494 82,393 77,546 
   iovera°5,260 4,467 13,645 10,694 
   Bupivacaine liposome injectable suspension858 2,957 2,241 5,469 
      Total net product sales$163,583 $166,560 $492,481 $492,563 
NOTE 4—INVENTORIES
The components of inventories, net are as follows (in thousands):
September 30,December 31,
20232022
Raw materials$49,196 $39,810 
Work-in-process23,765 28,853 
Finished goods23,559 27,400 
     Total$96,520 $96,063 
Pacira BioSciences, Inc. | Q3 2023 Form 10-Q | Page 12
NOTE 5—FIXED ASSETS
Fixed assets, net, summarized by major category, consist of the following (in thousands):
September 30,December 31,
20232022
Machinery and equipment$120,481 $118,684 
Leasehold improvements61,508 61,302 
Computer equipment and software16,242 15,360 
Office furniture and equipment2,543 2,420 
Construction in progress106,383 103,226 
        Total307,157 300,992 
Less: accumulated depreciation(131,374)(117,480)
        Fixed assets, net$175,783 $183,512 
For the three months ended September 30, 2023 and 2022, depreciation expense was $4.1 million and $5.8 million, respectively. For the three months ended September 30, 2023 and 2022, there was $0.7 million and $1.1 million of capitalized interest on the construction of manufacturing sites, respectively.
For the nine months ended September 30, 2023 and 2022, depreciation expense was $14.1 million and $18.0 million, respectively. For the nine months ended September 30, 2023 and 2022, there was $2.8 million and $2.9 million of capitalized interest on the construction of manufacturing sites, respectively.
At September 30, 2023 and December 31, 2022, total fixed assets, net includes manufacturing process equipment and leasehold improvements located in Europe in the amount of $38.3 million and $44.7 million, respectively.
As of September 30, 2023 and December 31, 2022, the Company had asset retirement obligations of $4.0 million and $3.3 million, respectively, included in accrued expenses and other liabilities on its condensed consolidated balance sheets, for costs associated with returning leased spaces to their original condition upon the termination of certain of its lease agreements.
NOTE 6—LEASES
The Company leases all of its facilities, including its EXPAREL and iovera° handpiece manufacturing facility at its Science Center Campus in San Diego, California. The Company also has two embedded leases with Thermo Fisher Scientific Pharma Services for the use of their manufacturing facility in Swindon, England for the production of EXPAREL and ZILRETTA. A portion of the associated monthly base fees has been allocated to the lease components based on a relative fair value basis.
Since July 2022 and February 2023, the Company has been recognizing sublease income for laboratory space leased in Woburn, Massachusetts and a portion of office space leased in Burlington, Massachusetts, respectively, from leases that were assumed as part of the Flexion Acquisition.
During the third quarter of 2023, the Company partially exited its Burlington, Massachusetts office space lease that had been assumed as part of the Flexion Acquisition through a one-time termination fee of $0.8 million, which released its obligation of $1.6 million in future cash payments for the respective proportion of square footage exited. The partial lease termination resulted in a nominal gain which was recorded within contingent consideration charges (gains), restructuring charges and other in the condensed consolidated statements of operations.
Pacira BioSciences, Inc. | Q3 2023 Form 10-Q | Page 13
The operating lease costs for the facilities include lease and non-lease components, such as common area maintenance and other common operating expenses, along with executory costs such as insurance and real estate taxes. Total operating lease expense, net is as follows (in thousands):
Three Months EndedNine Months Ended
September 30,September 30,
2023202220232022
Fixed lease costs$3,559 $3,440 $10,818 $10,509 
Variable lease costs499 540 1,444 1,520 
Sublease income(167)(169)(489)(169)
Total$3,891 $3,811 $11,773 $11,860 
Supplemental cash flow information related to operating leases is as follows (in thousands):
Nine Months Ended
September 30,
20232022
Cash paid for operating lease liabilities, net of lease incentives$11,055 $9,922 
The Company has elected to net the amortization of the right-of-use asset and the reduction of the lease liability principal in other liabilities in the condensed consolidated statements of cash flows.
The Company has measured its operating lease liabilities at an estimated discount rate at which it could borrow on a collateralized basis over the remaining term for each operating lease. The weighted average remaining lease terms and the weighted average discount rates are summarized as follows:
September 30,
20232022
Weighted average remaining lease term6.26 years7.11 years
Weighted average discount rate7.03 %6.95 %
Maturities of the Company’s operating lease liabilities are as follows (in thousands):
YearAggregate Minimum
Payments Due
2023 (remaining three months)$3,249 
202413,038 
202512,775 
202612,814 
202712,587 
Thereafter27,351 
   Total future lease payments81,814 
   Less: imputed interest(16,100)
   Total operating lease liabilities$65,714 


Pacira BioSciences, Inc. | Q3 2023 Form 10-Q | Page 14
NOTE 7—GOODWILL AND INTANGIBLE ASSETS
Goodwill
The Company’s goodwill results from the acquisition of Pacira Pharmaceuticals, Inc. (the Company’s California operating subsidiary) from SkyePharma Holding, Inc., or Skyepharma, (now a subsidiary of Vectura Group plc) in 2007 (the “Skyepharma Acquisition”), the MyoScience Acquisition in 2019 and the Flexion Acquisition in 2021. The balance at each of September 30, 2023 and December 31, 2022 was $163.2 million.
The Skyepharma Acquisition occurred in March 2007, prior to the requirements to record contingent consideration at fair value under ASC 805-30. In connection with the Skyepharma Acquisition, the Company agreed to certain milestone payments for DepoBupivacaine products, including EXPAREL. The final Skyepharma milestone payment of $32.0 million when annual net sales collected reached $500.0 million was achieved in the fourth quarter of 2021 and paid during the first quarter of 2022.
Intangible Assets
Intangible assets, net, consists of the in-process research and development, or IPR&D, and developed technology from the Flexion Acquisition and developed technology and customer relationships from the MyoScience Acquisition and are summarized as follows (dollar amounts in thousands):
September 30, 2023Gross Carrying ValueAccumulated AmortizationIntangible Assets, NetWeighted-Average Useful Lives
Developed technologies$590,000 $(127,336)$462,664 10 years, 5 months
Customer relationships90 (40)50 10 years
     Total finite-lived intangible assets, net590,090 (127,376)462,714 
Acquired IPR&D34,866 — 34,866 
     Total intangible assets, net$624,956 $(127,376)$497,580 
December 31, 2022Gross Carrying ValueAccumulated AmortizationIntangible Assets, NetWeighted-Average Useful Lives
Developed technologies$590,000 $(84,376)$505,624 10 years, 5 months
Customer relationships90 (34)56 10 years
     Total finite-lived intangible assets, net590,090 (84,410)505,680 
Acquired IPR&D34,866 — 34,866 
     Total intangible assets, net$624,956 $(84,410)$540,546 
Amortization expense on intangible assets was $14.3 million for both the three months ended September 30, 2023 and 2022 and $43.0 million for both the nine months ended September 30, 2023 and 2022.
Assuming no changes in the gross carrying amount of these intangible assets, the future estimated amortization expense on the finite-lived intangible assets will be $14.3 million for the remaining three months of 2023, $57.3 million each year from 2024 to 2030, $37.4 million in 2031, $7.9 million in 2032 and $2.2 million in 2033.
Pacira BioSciences, Inc. | Q3 2023 Form 10-Q | Page 15
NOTE 8—DEBT
The carrying value of the Company’s outstanding debt is summarized as follows (in thousands):
September 30,December 31,
20232022
Term loan A facility maturing March 2028$117,965 $— 
Term loan B facility maturing December 2026 (1)
— 284,704 
0.750% Convertible senior notes due August 2025
397,976 396,126 
3.375% Convertible senior notes due May 2024
8,641 8,641 
     Total$524,582 $689,471 
(1) The TLB Term Loan (as defined below) was refinanced on March 31, 2023 as discussed below.
2028 Term Loan A Facility
On March 31, 2023, the Company entered into a credit agreement (the “TLA Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders, to refinance the indebtedness outstanding under the Company’s TLB Credit Agreement (as defined and discussed below). The term loan issued under the TLA Credit Agreement (the “TLA Term Loan”) was issued at a 0.30% discount and provides for a single-advance term loan A facility in the principal amount of $150.0 million, which is secured by substantially all of the Company’s and any subsidiary guarantor’s assets. Subject to certain conditions, the Company may, at any time, on one or more occasion, add one or more new classes of term facilities and/or increase the principal amount of the loans of any existing class by requesting one or more incremental term facilities. The net proceeds of the TLA Term Loan were approximately $149.6 million after deducting an original issue discount of $0.4 million.

The total debt composition of the TLA Term Loan is as follows (in thousands):
September 30,
2023
Term loan A facility maturing March 2028$119,375 
Deferred financing costs(1,013)
Discount on debt(397)
     Total debt, net of debt discount and deferred financing costs$117,965 
The TLA Term Loan matures on March 31, 2028 and the TLA Credit Agreement requires quarterly repayments of principal in the amount of $2.8 million which commenced on June 30, 2023, increasing to $3.8 million commencing March 31, 2025, with a remaining balloon payment of approximately $85.3 million due at maturity. Due to voluntary principal prepayments of $27.8 million made during the three months ended September 30, 2023, the Company is not required to make further principal payments for the remainder of 2023 and 2024.
The TLA Credit Agreement requires the Company to, among other things, maintain (i) a Senior Secured Net Leverage Ratio (as defined in the TLA Credit Agreement), determined as of the last day of each fiscal quarter, of no greater than 3.00 to 1.00 and (ii) a Fixed Charge Coverage Ratio (as defined in the Credit Agreement), determined as of the last day of each fiscal quarter, of no less than 1.50 to 1.00. The TLA Credit Agreement also contains customary affirmative and negative covenants, financial covenants, representations and warranties, events of default and other provisions. As of September 30, 2023, the Company was in compliance with all financial covenants under the TLA Credit Agreement.
The Company may elect to borrow either (i) alternate base rate borrowings or (ii) term benchmark borrowings or daily simple SOFR (as defined in the TLA Credit Agreement) borrowings. Each term loan borrowing that is an alternate base rate borrowing bears interest at a rate per annum equal to (i) the Alternate Base Rate (as defined in the TLA Credit Agreement), plus (ii) a spread based on the Company’s Senior Secured Net Leverage Ratio ranging from 2.00% to 2.75%. Each term loan borrowing that is a term benchmark borrowing or daily simple SOFR borrowing bears interest at a rate per annum equal to (i) the Adjusted Term SOFR Rate or Adjusted Daily Simple SOFR (as each is defined in the Credit Agreement), plus (ii) a spread based on the Company’s Senior Secured Net Leverage Ratio ranging from 3.00% to 3.75%. During the nine months ended September 30, 2023, the Company made a scheduled principal payment of $2.8 million as well as $27.8 million of voluntary principal prepayments. As of September 30, 2023, borrowings under the TLA Term Loan consisted entirely of term benchmark borrowings at a rate of 8.47%.
Pacira BioSciences, Inc. | Q3 2023 Form 10-Q | Page 16
2026 Term Loan B Facility
In December 2021, the Company entered into a term loan credit agreement (the “TLB Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent and the initial lender. The term loan issued under the Credit Agreement (the “TLB Term Loan”) was issued at a 3.00% discount and allowed for a single-advance term loan B facility in the principal amount of $375.0 million, which was secured by substantially all of the Company’s and each subsidiary guarantor’s assets. The net proceeds of the TLB Term Loan were approximately $363.8 million after deducting an original issue discount of $11.2 million.
On March 31, 2023, the Company used the $149.6 million of net borrowings under the TLA Credit Agreement and cash on hand to repay the indebtedness outstanding under the TLB Credit Agreement and concurrently terminated the TLB Credit Agreement. The Company incurred a prepayment fee of 2.00% of the outstanding principal balance of the TLB Term Loan in connection with the termination.
The total debt composition of the TLB Term Loan was as follows (in thousands):
September 30,December 31,
20232022
Term loan B facility maturing December 2026$— $296,875 
Deferred financing costs— (3,919)
Discount on debt— (8,252)
     Total debt, net of debt discount and deferred financing costs$— $284,704 
During the nine months ended September 30, 2023, the Company made a scheduled principal payment of $9.4 million and repaid the outstanding $287.5 million principal on the TLB Term Loan, which resulted in a $16.9 million loss on early extinguishment of debt.
Convertible Senior Notes Due 2025
In July 2020, the Company completed a private placement of $402.5 million in aggregate principal amount of its 0.750% convertible senior notes due 2025, or 2025 Notes, and entered into an indenture with Computershare Corporate Trust, N.A. (formerly Wells Fargo Bank, N.A.), or 2025 Indenture, with respect to the 2025 Notes. The 2025 Notes accrue interest at a fixed rate of 0.750% per year, payable semiannually in arrears on February 1st and August 1st of each year. The 2025 Notes mature on August 1, 2025.
The total debt composition of the 2025 Notes is as follows (in thousands):
September 30,December 31,
20232022
0.750% convertible senior notes due August 2025
$402,500 $402,500 
Deferred financing costs(4,524)(6,374)
     Total debt, net of debt discount and deferred financing costs$397,976 $396,126 
The net proceeds from the issuance of the 2025 Notes were approximately $390.0 million, after deducting commissions and the offering expenses paid by the Company. A portion of the net proceeds from the 2025 Notes was used by the Company to repurchase $185.0 million in aggregate principal amount of its then-outstanding 2.375% convertible senior notes due 2022 in privately-negotiated transactions for a total of $211.1 million of cash (including accrued interest).
Holders may convert the 2025 Notes at any time prior to the close of business on the business day immediately preceding February 3, 2025, only if certain circumstances are met, including if during the previous calendar quarter, the last reported sales price of the Company’s common stock was greater than 130% of the conversion price then applicable for at least 20 out of the last 30 consecutive trading days of the quarter. During the quarter ended September 30, 2023, the conditions for conversion were not met.
On or after February 3, 2025, until the close of business on the second scheduled trading day immediately preceding August 1, 2025, holders may convert their 2025 Notes at any time.
Upon conversion, holders will receive the principal amount of their 2025 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the 40 consecutive trading days during the observation period (as more fully described in the 2025 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s option. The initial conversion rate for the 2025 Notes is 13.9324 shares of common stock per $1,000
Pacira BioSciences, Inc. | Q3 2023 Form 10-Q | Page 17
principal amount, which is equivalent to an initial conversion price of $71.78 per share of the Company’s common stock. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2025 Notes represents a premium of approximately 32.5% to the closing sale price of $54.17 per share of the Company’s common stock on the Nasdaq Global Select Market on July 7, 2020, the date that the Company priced the private offering of the 2025 Notes.
As of September 30, 2023, the 2025 Notes had a market price of $909 per $1,000 principal amount. In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2025 Notes will be paid pursuant to the terms of the 2025 Indenture. In the event that all of the 2025 Notes are converted, the Company would be required to repay the $402.5 million in principal value and any conversion premium in any combination of cash and shares of its common stock (at the Company’s option).
Beginning on August 1, 2023 (but, in the case of a redemption of less than all of the outstanding 2025 Notes, no later than the 40th scheduled trading day immediately before the maturity date), the Company may redeem for cash all or part of the 2025 Notes if the last reported sale price (as defined in the 2025 Indenture) of the Company’s common stock has been at least 130% of the conversion price then in effect for (i) each of at least 20 trading days (whether or not consecutive) during any 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related notice of redemption and (ii) the trading day immediately before the date the Company sends such notice. The redemption price will equal the sum of (i) 100% of the principal amount of the 2025 Notes being redeemed, plus (ii) accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. In addition, calling the 2025 Notes for redemption will constitute a “make-whole fundamental change” (as defined in the 2025 Indenture) and will, in certain circumstances, increase the conversion rate applicable to the conversion of such notes if it is converted in connection with the redemption. No sinking fund is provided for the 2025 Notes.
While the 2025 Notes are currently classified on the Company’s condensed consolidated balance sheet at September 30, 2023 as long-term debt, the future convertibility and resulting balance sheet classification of this liability is monitored at each quarterly reporting date and is analyzed dependent upon market prices of the Company’s common stock during the prescribed measurement periods. In the event that the holders of the 2025 Notes have the election to convert the 2025 Notes at any time during the prescribed measurement period, the 2025 Notes would then be considered a current obligation and classified as such.
Convertible Senior Notes Due 2024 Assumed from the Flexion Acquisition
Prior to the Flexion Acquisition, on May 2, 2017, Flexion issued an aggregate of $201.3 million principal amount of 3.375% convertible senior notes due 2024 (the “Flexion 2024 Notes”), pursuant to the indenture, dated as of May 2, 2017 (the “Original Flexion Indenture”), between Flexion and Computershare Corporate Trust, N.A. (formerly Wells Fargo Bank, N.A.), as trustee (the “Flexion Trustee”), as supplemented by the First Supplemental Indenture, dated as of November 19, 2021, between Flexion and the Flexion Trustee (the “First Supplemental Flexion Indenture” and, together with the Original Flexion Indenture, the “Flexion Indenture”). The Flexion 2024 Notes mature on May 1, 2024, are unsecured and accrue interest at a rate of 3.375% per annum, payable semi-annually on May 1st and November 1st of each year. Upon the Flexion Acquisition, the principal was assumed and recorded at fair value by the Company.
As a result of the Flexion Acquisition, and in connection with a Fundamental Change Company Notice and Offer to Purchase (the “Notice”) to the holders of the Flexion 2024 Notes in accordance with the Flexion Indenture, holders of the Flexion 2024 Notes became entitled to certain Flexion Acquisition-related conversion and repurchase rights. On December 6, 2021, as a result of the Flexion Acquisition and in accordance with the Flexion Indenture, the Company offered to repurchase for cash all of the outstanding Flexion 2024 Notes, at a repurchase price in cash equal to 100% of the principal amount of the Flexion 2024 Notes being repurchased, plus accrued and unpaid interest thereon to, but excluding, January 7, 2022, subject to the terms and conditions set forth therein. Any holder that did not exercise its repurchase right in accordance with the terms of the Notice retained the conversion rights associated with such holder’s Flexion 2024 Notes under the Flexion Indenture as well as the right to receive interest payments on the Flexion 2024 Notes.
On January 7, 2022, following the expiration of the offer to purchase, the Company accepted the $192.6 million aggregate principal amount of Flexion 2024 Notes that were validly tendered (and not validly withdrawn). No Flexion 2024 Notes were converted in connection with the Notice. At September 30, 2023, the remaining principal outstanding is $8.6 million.
Pacira BioSciences, Inc. | Q3 2023 Form 10-Q | Page 18
Convertible Senior Notes Due 2022
In March 2017, the Company completed a private placement of $345.0 million in aggregate principal amount of 2.375% convertible senior notes due 2022, or 2022 Notes, and entered into an indenture with respect to the 2022 Notes. On April 1, 2022, the 2022 Notes matured and the Company settled the remaining outstanding principal balance of $160.0 million and a conversion premium of $4.8 million through a cash payment of $156.9 million and the issuance of 101,521 shares of the Company’s common stock, which increased additional paid-in capital by $3.0 million.
Interest Expense
The following table sets forth the total interest expense recognized in the periods presented (dollar amounts in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Contractual interest expense$3,471 $9,343 $16,670 $26,724 
Amortization of debt issuance costs683 903 2,311 2,956 
Amortization of debt discount25 695 728 2,107 
Capitalized interest and other (Note 5)
(715)(1,085)(2,791)(2,852)
        Total$3,464 $9,856 $16,918 $28,935 
Effective interest rate on total debt2.98 %5.42 %3.96 %5.66 %
NOTE 9—FINANCIAL INSTRUMENTS
Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in the principal or most advantageous market in an orderly transaction. To increase consistency and comparability in fair value measurements, the Financial Accounting Standards Board (FASB) established a three-level hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of fair value measurements are:
•Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
•Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.
•Level 3: Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
The carrying value of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximate their respective fair values due to the short-term nature of these items. The fair value of the Company’s convertible senior notes are calculated utilizing market quotations from an over-the-counter trading market for these notes (Level 2). The fair value of the Company’s acquisition-related contingent consideration is reported at fair value on a recurring basis (Level 3). The carrying amounts of equity investments and convertible notes receivable without readily determinable fair values have not been adjusted for either an impairment or upward or downward adjustments based on observable transactions.
Pacira BioSciences, Inc. | Q3 2023 Form 10-Q | Page 19
At September 30, 2023, the carrying values and fair values of the following financial assets and liabilities were as follows (in thousands):
Carrying ValueFair Value Measurements Using
Level 1Level 2Level 3
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Financial Assets:
Equity investments$15,877 $— $— $15,877 
Convertible notes receivable$11,938 $— $— $11,938 
Financial Liabilities:
   Acquisition-related contingent consideration$24,275 $— $— $24,275 
Financial Liabilities Measured at Amortized Cost:
Term loan A facility due March 2028$117,965 $— $118,778 $— 
   0.750% convertible senior notes due 2025 (1)
$397,976 $— $365,772 $— 
   3.375% convertible senior notes due 2024
$8,641 $— $8,641 $— 
(1) The closing price of the Company’s common stock as reported on the Nasdaq Global Select Market was $30.68 per share at September 30, 2023 compared to a conversion price of $71.78 per share. At September 30, 2023, as the conversion price was above the stock price, the requirements for conversion have not been met. The maximum conversion premium that could have been due on the 2025 Notes is 5.6 million shares of the Company’s common stock, which assumes no increase in the conversion rate for certain corporate events.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Equity and Convertible Note Investments
The Company holds strategic investments in clinical and preclinical stage privately-held biotechnology companies in the form of equity and convertible note investments. The following investments have no readily determinable fair value and are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments (in thousands):
Equity InvestmentsConvertible Notes ReceivableTotal
Balance at December 31, 2021
$14,127 $4,132 $18,259 
   Purchases11,750 1,250 13,000 
   Impairment(10,000)— (10,000)
   Foreign currency adjustments— (67)(67)
Balance at December 31, 2022
15,877 5,315 21,192 
   Purchases— 6,758 6,758 
   Foreign currency adjustments— (135)(135)
Balance at September 30, 2023
$15,877 $11,938 $27,815 
Acquisition-Related Contingent Consideration
The Company has recognized contingent consideration related to the Flexion Acquisition and the MyoScience Acquisition in the amount of $24.3 million and $28.1 million as of September 30, 2023 and December 31, 2022, respectively. For more information, see Note 14, Contingent Consideration Charges (Gains), Restructuring Charges and Other.
The Company’s contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period if and until the related contingencies are resolved. The Company has measured the fair value of its contingent consideration using a probability-weighted discounted cash flow approach that is based on unobservable inputs and a Monte Carlo simulation. These inputs include, as applicable, estimated probabilities and the timing of achieving specified commercial and regulatory milestones, estimated forecasts of revenue and costs and the discount rates used to calculate the present value of estimated future payments. Significant changes may increase or decrease the probabilities of achieving the related commercial and regulatory events, shorten or lengthen the time required to achieve such events, or increase or decrease estimated forecasts.
Pacira BioSciences, Inc. | Q3 2023 Form 10-Q | Page 20
In November 2021, the Company completed the Flexion Acquisition, which provided for contingent consideration related to contingent value rights that were issued to Flexion shareholders and certain equity award holders which could aggregate up to a total of $372.3 million if certain regulatory and commercial milestones are met. The aggregate amount was initially $425.5 million prior to the Company’s September 2022 decision to formally discontinue further development of Flexion’s product candidate, PCRX-301. The Company’s obligation to make milestone payments is limited to those milestones achieved through December 31, 2030, and are to be paid within 60 days of the end of the fiscal quarter of achievement. During the three months ended September 30, 2023, the Company recorded charges of $2.8 million primarily due to market volatility which affects the liability’s present value. During the nine months ended September 30, 2023, the Company recorded gains of $3.8 million due to adjustments to long-term forecasts which reduced the probability of meeting the sales-based contingent consideration milestones by December 31, 2030, the expiration date for achieving the milestones. The gains recognized during the nine months ended September 30, 2023 were partially offset by a decrease in the assumed discount rate that is utilized in calculating the liability’s present value, based on a significant improvement in the Company’s incremental borrowing rate resulting from the TLA Credit Agreement entered into in March 2023. During the three and nine months ended September 30, 2022, the Company recorded gains of $0.5 million and $13.8 million, respectively, primarily due to adjustments to near-term forecasts for the earnout period of the contingent consideration. These adjustments were recorded as contingent consideration charges (gains), restructuring charges and other in the condensed consolidated statements of operations. At September 30, 2023, the weighted average discount rate was 10.6% and the probability of payment for the achievement of the remaining regulatory milestone by the expiration date was 12.5%. As of September 30, 2023 and December 31, 2022, a contingent consideration liability related to the Flexion Acquisition was recognized in the amount of $24.3 million and $28.1 million, respectively.
In April 2019, the Company completed the MyoScience Acquisition pursuant to the terms of an Agreement and Plan of Merger, which provided for contingent milestone payments of up to an aggregate of $100.0 million upon the achievement of certain regulatory and commercial milestones. The Company’s obligation to make milestone payments is limited to those milestones achieved through December 31, 2023, and are to be paid within 60 days of the end of the fiscal quarter of achievement. As of September 30, 2023, the maximum potential remaining milestone payments to be paid are $43.0 million. At September 30, 2023, the probability of success for the regulatory milestone that has not yet been met was assessed as zero. As of September 30, 2023 and December 31, 2022, a contingent consideration liability related to the MyoScience Acquisition has been assessed as zero. During the three and nine months ended September 30, 2022, the Company recognized contingent consideration gains of $0.5 million and $9.6 million, respectively, due to the reduced probability of meeting the contingent consideration milestones by December 31, 2023, the expiration date for achieving the milestones.
The following table includes the key assumptions used in the valuation of the Company’s contingent consideration:
Assumption
Flexion Ranges
Utilized as of
September 30, 2023
Discount rates
10.1% to 11.1%
Probabilities of payment for regulatory milestones
0% to 12.5%
Projected year of payment for regulatory and commercial milestones
2030
The change in the Company’s contingent consideration recorded at fair value using Level 3 measurements is as follows (in thousands):
Contingent Consideration
Fair Value
Balance at December 31, 2021
$57,598 
Fair value adjustments and accretion(29,476)
Balance at December 31, 2022
28,122 
   Fair value adjustments and accretion(3,847)
Balance at September 30, 2023
$24,275 
Available-for-Sale Investments
Short-term investments consist of asset-backed securities collateralized by credit card receivables, investment grade commercial paper and corporate, federal agency and government bonds with maturities greater than three months, but less than one year. Noncurrent investments consist of federal agency bonds and government bonds with maturities greater than one year but less than three years. Net unrealized gains and losses (excluding credit losses, if any) from the Company’s short-term investments are reported in other comprehensive income (loss). At September 30, 2023 and December 31, 2022, all of the
Pacira BioSciences, Inc. | Q3 2023 Form 10-Q | Page 21
Company’s short-term and noncurrent investments are classified as available-for-sale investments and are determined to be Level 2 instruments, which are measured at fair value using standard industry models with observable inputs. The fair value of the commercial paper is measured based on a standard industry model that uses the three-month U.S. Treasury bill rate as an observable input. The fair value of the asset-backed securities and corporate bonds is principally measured or corroborated by trade data for identical issues in which related trading activity is not sufficiently frequent to be considered a Level 1 input or that of comparable securities. At the time of purchase, all available-for-sale investments had an “A” or better rating by Standard & Poor’s. 
The following summarizes the Company’s short-term and noncurrent available-for-sale investments at September 30, 2023 and December 31, 2022 (in thousands):
September 30, 2023 Investments
CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
(Level 2)
Current:
Asset-backed securities$15,473 $— $(32)$15,441 
Commercial paper65,781 1 (110)65,672 
U.S. federal agency bonds40,332 — (116)40,216 
U.S. government bonds14,797 — (57)14,740 
          Total$136,383 $1 $(315)$136,069 
December 31, 2022 Investments
CostGross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
(Level 2)
Current:
Asset-backed securities$6,836 $— $(3)$6,833 
Commercial paper134,423 23 (386)134,060 
U.S. federal agency bonds41,971 — (337)41,634 
U.S. government bonds2,003 — (18)1,985 
Subtotal$185,233 $23 $(744)$184,512 
Noncurrent:
U.S. federal agency bonds22,783 2 (66)22,719 
U.S. government bonds14,499 — (9)14,490 
Subtotal37,282 2 (75)37,209 
          Total$222,515 $25 $(819)$221,721 
At September 30, 2023, there were no investments available for sale that were materially less than their amortized cost.
The Company elects to recognize its interest receivable separate from its available-for-sale investments. At September 30, 2023 and December 31, 2022, the interest receivable from its available-for-sale investments recognized in prepaid expenses and other current assets was $0.4 million and $0.8 million, respectively.
Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term and long-term available-for-sale investments and accounts receivable. The Company maintains its cash and cash equivalents with high-credit quality financial institutions. Such amounts may exceed federally-insured limits.
 As of September 30, 2023, three wholesalers each accounted for over 10% of the Company’s accounts receivable, at 37%, 18% and 15%. At December 31, 2022, three wholesalers each accounted for over 10% of the Company’s accounts receivable, at 34%, 19% and 18%. For additional information regarding the Company’s wholesalers, see Note 2, Summary of Significant Accounting Policies. EXPAREL and ZILRETTA revenues are primarily derived from major wholesalers and specialty distributors that generally have significant cash resources. The Company performs ongoing credit evaluations of its customers as warranted and generally does not require collateral. Allowances for credit losses on the Company’s accounts receivable are maintained based on historical payment patterns, current and estimated future economic conditions, aging of accounts receivable and its write-off history. As of September 30, 2023 and December 31, 2022, the Company did not deem any allowances for credit losses on its accounts receivable necessary.
Pacira BioSciences, Inc. | Q3 2023 Form 10-Q | Page 22
NOTE 10—STOCKHOLDERS’ EQUITY
Accumulated Other Comprehensive Loss
The following tables illustrate the changes in the balances of the Company’s accumulated other comprehensive loss for the periods presented (in thousands):
Net Unrealized Gain (Loss) From Available-For-Sale InvestmentsUnrealized Foreign Currency TranslationAccumulated Other Comprehensive Loss
Balance at December 31, 2022
$(523)$143 $(380)
   Net unrealized gain on investments, net of tax (1)
362 — 362 
   Foreign currency translation adjustments— 8 8 
Balance at September 30, 2023
$(161)$151 $(10)
Net Unrealized (Loss) Gain From Available-For-Sale InvestmentsUnrealized Foreign Currency TranslationAccumulated Other Comprehensive (Loss) Income
Balance at December 31, 2021
$139 $28 $167 
   Net unrealized loss on investments, net of tax (1)
(1,056)— (1,056)
   Foreign currency translation adjustments— 219 219 
Balance at September 30, 2022
$(917)$247 $(670)
(1) Net of a $0.2 million tax expense and $0.3 million tax benefit for the nine months ended September 30, 2023 and 2022, respectively.
NOTE 11—STOCK PLANS
Stock Incentive Plans